Effect of anti-obesity agent HSG4112 on overweight and obese patients following 12 weeks of oral treatment: a study protocol for a randomised, double-blind, placebo-controlled, parallel-group, phase 2a clinical trial

Effect of anti-obesity agent HSG4112 on overweight and obese patients following 12 weeks of oral treatment: a study protocol for a randomised, double-blind, placebo-controlled, parallel-group, phase 2a clinical trial

Background: Glaceum Inc. has proposed HSG4112, a structural analogue of glabridin, as a novel anti-obesity compound. Animal studies and phase I human trials have shown that HSG4112 improves energy consumption, normalises weight, and is safe and drug-resistant. Based on these results, the company pla...

Full description

Bibliographic Details
Main Authors: Kyungha Min, Bumjo Oh, Hye Yeon Koo, Yang-Hyun Kim, Ji-Won Lee, Sangsub Lee, Youngah Kim, Hyuktae Kwon
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Pharmacology
Subjects:
obesity
overweight
weight loss
obesity drug
randomised controlled trial
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1177539/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1177539/full

Similar Items